GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 2024
· 2025
DOI: 10.15620/cdc/174616 ↗Kurz gefasst
Fachartikel, 2025. Verfasst von Anjel Vahratian und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Hypoglycemic Agents, Diabetes Mellitus. Die Arbeit wurde bisher 19-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
This report describes the percentage of adults with diagnosed diabetes who were taking an injectable glucagon-like peptide-1 (GLP-1) receptor agonist at the time of the interview by selected characteristics based on data from the 2024 National Health Interview Survey (NHIS).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Vahratian, A., & Warren, A. (2025). GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 2024. . https://doi.org/10.15620/cdc/174616
Vancouver
Vahratian A, Warren A. GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 2024. 2025. doi:10.15620/cdc/174616
BibTeX
@article{Vahratian2025,
author = {Vahratian, Anjel and Warren, Antonia},
title = {GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 2024},
year = {2025},
doi = {10.15620/cdc/174616}
}
EUVIMED